

RECEIVED
CENTRAL FAX CENTER

FEB 18 2004

OFFICIAL

Bereskin & Parr

INTELLECTUAL PROPERTY LAW

Scotia Plaza, 40 King Street West, 40th Floor
Toronto, Ontario, Canada M5H 3Y2
t: 416 364 7311 f: 416 361 1398TELEFAX TRANSMITTAL

TO: United States Patent and Trademark Office

ATTN: Jeffrey S. Parkin – Examiner, Art Unit 1648

FAX NO.: 703-872-9306 Tel: 571-272-0908

RE: Serial No. 09/762,294 Our file: 9611-16

FROM: Micheline Gravelle, Registration No. 40,261

DATE: February 18, 2004 PAGES: 8
(Including cover sheet)

If transmission is interrupted or of poor quality, please notify us immediately by calling Jenny Lo at (416) 364-7311, ext. 6277.

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the attached Response and Petition for Extension of Time are being facsimile transmitted to the U.S. Patent & Trademark Office on the date shown below.



Micheline Gravelle
Registration No. 40,261

February 18, 2004
Date

CONFIDENTIAL

This communication may contain information that is privileged or confidential and is intended only for the use of the individual to whom it is addressed. Any other distribution, copying or disclosure is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us by mail. Thank you.

RECEIVED
CENTRAL FAX CENTER

FEB 18 2004

Appl. No. 09/762,294
Amdt. Dated February 18, 2004
Reply to Office action of October 22, 2003

OFFICIAL

Confirmation No.: 4835

Appl. No : 09/762,294
Applicants : Chil-Yong Kang and Yan Li
Filed : April 2, 2001
Title : HIV Vaccine
TC./A.U. : 1648
Examiner : Jeffrey S. Parkin

Docket No. : 9611-16
Customer No. : 001059

BY FACSIMILE

Honorable Commissioner for Patents
P. O. Box 1450
Alexandria, Virginia 22313-1450

AMENDMENT

Sir:

The present letter is filed in response to the office action dated October 22, 2003. Applicant is simultaneously submitting a petition for a one month extension of time rendering the deadline for reply February 22, 2004. Please amend the above-identified application as follows.

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.